US FDA approves crizotinib for treatment of ALK-positive anaplastic large cell lymphoma (ALCL) in children aged 1 year and above and young adults

ALCL accounts for approximately 30% of cases of non-Hodgkin lymphoma in young people (90% ALK-positive). The approval was based on the results of a single-arm open-label study, in which crizotinib was associated with an objective response rate of 88%.

Biospace Inc.